GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
- 1 January 2023
- journal article
- research article
- Published by Mary Ann Liebert Inc in Clinical Thyroidology
- Vol. 35 (1)
- https://doi.org/10.1089/ct.2023;35.18-20
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- GLP-1 Receptor Agonists and the Risk of Thyroid CancerDiabetes Care, 2022
- Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)Diabetes Care, 2019
- Weight change is significantly associated with risk of thyroid cancer: A nationwide population-based cohort studyScientific Reports, 2019
- Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort studyDiabetes, Obesity and Metabolism, 2018
- No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER TrialDiabetes Care, 2017
- Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in RodentsEndocrinology, 2015
- Obesity and Thyroid Cancer: A Clinical UpdateThyroid®, 2014
- A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancerDiabetes Research and Clinical Practice, 2012